Dibotermin alfa Other names: Divotermine alpha

Therapeutic indications

Dibotermin alfa is indicated for:

Single-level lumbar interbody spine fusion

Population group: only adults (18 - 65 years old)

Dibotermin alfa is indicated for single-level lumbar interbody spine fusion as a substitute for autogenous bone graft in adults with degenerative disc disease who have had at least 6 months of non-operative treatment for this condition.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Acute tibia fracture

Population group: only adults (18 - 65 years old)

Dibotermin alfa is indicated for the treatment of acute tibia fractures in adults, as an adjunct to standard care using open fracture reduction and intramedullary unreamed nail fixation.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Dibotermin alfa is contraindicated in the following cases:

Skeletal immaturity

Congenital anomaly of skeletal bone

Malignancy

Malignant tumour

Active infection at the operative site

Infection associated with implant

Compartment syndrome

Compartment syndrome

Pathological fractures

Pathological fracture

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2018: INDUCTOS Powder, solvent and matrix for implantation matrix
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈